ORCHESTRA BIOMED HOLDINGS INC (OBIO)
Health Care · Cardiovascular medical devices and bioelectronic therapies · NASDAQ
Orchestra BioMed develops late-stage bioelectronic and interventional cardiovascular therapies through risk-sharing partnerships with major device makers, focused on hypertension and coronary artery disease.
What ORCHESTRA BIOMED HOLDINGS INC does
Orchestra BioMed is a biomedical innovation company developing late-stage clinical medical device candidates through strategic partnerships with market-leading device manufacturers. The company's flagship programs are AVIM Therapy, a bioelectronic treatment for hypertension integrated into cardiac pacemakers (in collaboration with Medtronic), and Virtue Sirolimus AngioInfusion Balloon, a drug-coated balloon for coronary artery disease. The company operates under a risk-reward-sharing partnership model with major medical device companies.
Themes: bioelectronic therapy / cardiac devices, hypertension treatment, coronary artery disease / restenosis, drug-coated balloons, pacemaker technology, medical device partnerships
Fundamentals
- Price$5.36 as of 2026-08-21 close
- Market cap$322M as of 2026-08-21
- 1-year return+115.3% 2025-08-21 close $2.49 → 2026-08-21 close $5.36
- P/En/a negative earnings
- Net margin-166.8% as of 2026-08-24
- Gross margin+99.5% as of 2026-08-24
- ROE-137.8% as of 2026-08-24
- Debt / equity0.28 as of 2026-08-24
- Revenue growth (YoY)+1169.2% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)+111.6% SEC XBRL
- Beta0.56 as of 2026-08-24
- Last reported earningsn/a no earnings announcement (Form 8-K, Item 2.02) has been filed in our data yet
How OBIO compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which OBIO reported a dividend payment is FY2022, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2022 ratio would not describe OBIO today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2022) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How ORCHESTRA BIOMED HOLDINGS INC looks technically
ORCHESTRA BIOMED HOLDINGS INC (OBIO) is trading 27.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 32 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 27.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +27.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.16 | $4.16 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.21 | $4.21 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 29 calendar days ago — the swings before that are what the structure reading is measured on | 29 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 32 trading days ago — a "death cross", a bearish long-term signal | 32 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 27.2% above | +27.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control | 35.5 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70) | 72.5 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($4.03 to $5.78) — its "stochastic" reading is 76 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 76.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.78 | $5.78 |
|---|---|---|
| From the 52-week high | it is 7.3% below its 52-week high (its highest price of the past year) | -7.3% |
| Above the 52-week low | it is 143.6% above its 52-week low (its lowest price of the past year) | +143.6% |
| Below the 52-week high | it is 7.3% below its highest point of the past year | 7.3% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $23.39 (set on 2023-04-03) | $23.39 |
| Given back of the 52-week move | over the past year its closes ranged ($2.35 to $5.66), and it has given back only a small part of its rise from last year’s low — 9% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.51 to $3.61. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 9.1% |
| From the all-time high | it is 77.1% below its all-time high | -77.1% |
| Nearest price level | it is trading 1.4% below a resistance level at $5.44 — a price it turned at twice since 2024-09-30, most recently on 2025-11-26. Since 2024-08-21 it has 13 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $2.20 (set on 2025-09-24) | $2.20 |
| Above the all-time low | it is 143.6% above its all-time low | +143.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2727 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2727 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.33 and $5.60 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.33 – $4.47 – $5.60 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges above its 200-day average price (27.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.04× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.4% |
|---|---|---|
| Gap filled | a 3.0% gap down opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -5.3% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 42.9 percentage points (the stock gained 45.3% while the market gained 2.3%) | +42.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 27.6 percentage points (the stock gained 30.7% while the market gained 3.1%) | +27.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 25.7 percentage points (the stock gained 36.7% while the market gained 11.1%) | +25.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 94.8 percentage points (the stock gained 115.3% while the market gained 20.5%) | +94.8% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.6% of the share price. | +27.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 26% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.26 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +25.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $5.26 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +1.9% |
Price levels it has turned at before
OBIO last closed at $5.36 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.44 | Resistance | 1.4% above the last close | turned there twice · 2024-09-30 to 2025-11-26 |
| $5.00 | Support | 6.8% below the last close | turned there five times · 2024-11-01 to 2026-01-09 |
| $4.88 | Support | 9.0% below the last close | turned there twice · 2024-12-06 to 2026-03-10 |
| $5.99 | Resistance | 11.7% above the last close | turned there twice · 2024-10-16 to 2025-02-19 |
| $4.73 | Support | 11.8% below the last close | turned there four times · 2024-10-10 to 2026-04-17 |
| $6.13 | Resistance | 14.4% above the last close | turned there twice · 2024-11-29 to 2025-02-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · in a strong, established uptrend (ADX) · beating the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.43 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$12.33 range $9.00 – $20.00; median $10.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OBIO
- Consensus EPS estimate-$0.372 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: BACKBEAT study enrollment targeted for mid-2026 with 500 patients; Virtue SAB trial enrollment targeted through mid-2027 with 740 patients; failure to enroll or achieve efficacy endpoints could derail both flagship programs","Dependence on strategic partnerships: exclusive collaboration with Medtronic for AVIM Therapy and comparison against Boston Scientific's AGENT balloon for Virtue SAB; partners control commercialization timelines and market access","Significant operating losses and cash burn: net margin of -166.75%, cumulative accumulated deficit of $383.3 million as of March 2026, with cash and equivalents of $28.4 million; company will require additional capital to fund ongoing clinical trials"]
What changed in the latest 10-Q
AI-assisted comparison of OBIO's 10-Q filed 2026-05-12 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-12) references Annual Report on Form 10-K for year ended December 31, 2025 filed March 12, 2026
- Newer filing adds description that AVIM Therapy is 'designed to be delivered by a pacemaker'
- Newer filing specifies BACKBEAT Trial enrollment 'currently targeted to be completed by the end of the third quarter of 2026'
- Newer filing adds FDA Breakthrough Device Designation details: 'as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk'
- Newer filing describes Virtue SAB as 'first-of-its-kind non-coated drug delivery angioplasty balloon system' and 'large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™'
- Newer filing specifies Virtue SAB BDD indications: 'coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease, in each case, within specified parameters'
- Newer filing states cumulative raised proceeds 'As of March 31, 2026, we have raised a cumulative $367.2 million'
- Newer filing adds: 'In May 2026, we received $20.0 million pursuant to the Medtronic Loan Agreement' and '$15.0 million from Ligand'
- Newer filing reports three-month net losses: '$20.7 million and $18.8 million for the three months ended March 31, 2026 and 2025, respectively'
- Newer filing states accumulated deficit 'As of March 31, 2026, we had an accumulated deficit of $383.3 million'
- Newer filing adds section 'Recent Developments' with subsection 'Orchestra BioMed Presented AVIM Therapy Clinical and Mechanistic Data at HRS 2026'
- Newer filing includes MODERATO II study data from April 23, 2026 presentation detailing blood pressure reductions and patient outcomes
- Removed:
- Older filing (2025-11-10) section 'Closing of Business Combination' is removed in newer filing
- Older filing references Form 10-K for year ended December 31, 2024 filed March 31, 2025 (replaced with 2025 reference)
- Older filing describes BACKBEAT 'enrolling up to 500 patients' (changed to 316 in newer)
- Older filing states enrollment completion 'in mid-2026' for BACKBEAT (changed to 'end of the third quarter of 2026')
- Older filing describes AVIM Therapy and Virtue SAB separately without detailed mechanism descriptions present in newer
- Older filing references 'Terumo Agreement' as funding source (replaced with 'Termination and ROFR Agreement' language in newer)
- Older filing states cumulative proceeds 'As of September 30, 2025, we have raised a cumulative $334.9 million'
- Older filing states 'Future committed cash receipts expected in April 2026' language (moved to actual receipt language in newer)
- Older filing reports nine-month net losses of '$58.9 million and $44.9 million for the nine months ended September 30, 2025 and 2024'
- Older filing states accumulated deficit 'As of September 30, 2025, we had an accumulated deficit of $368.8 million'
- Older filing includes 'Initiation of the Virtue Trial' Recent Developments subsection dated October 27, 2025 (replaced with April 2026 data presentation)
- Reworded:
- Older: 'Our flagship product candidates are' / Newer: 'Our two flagship product candidates – [full names] – are currently undergoing'
- Older: 'one of the largest medical device companies in the world and the global leader in cardiac pacing therapies' added in newer for Medtronic description
- Older: describes Virtue SAB generally / Newer: describes as 'highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system' with SirolimusEFR™ formulation detail
- Older: 'drug coated balloon' / Newer: 'drug-coated balloon'
- Older: 'enrollment completion currently planned for mid-2027' / Newer: 'enrollment completion currently planned for 2027'
- Older: 'sale of strategic investments' not mentioned in newer
- Older: references 'our distribution agreement with Terumo (the "Terumo Agreement")' / Newer: references 'our prior Terumo Agreement' and 'the Termination and ROFR Agreement'
- Notes:
- Newer filing excerpt appears truncated at end of MODERATO II data section
- Older filing excerpt appears truncated in Recent Developments section
- Comparison reflects different reporting periods: newer is Q1 2026 (three months to March 31, 2026), older is nine months to September 30, 2025
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 3 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($61350) — 1 selling insider
- Last 90 days1 buy ($19150) · 3 sells ($183450) — 1 buying, 1 selling insiders
- Last 180 days5 buys ($158081) · 4 sells ($183582) — 3 buying, 2 selling insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of OBIO within a 30-day window between 2026-05-14 and 2026-06-01. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OBIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding OBIO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 973,285
- Reported value $4,136,462
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OBIO had 2,425,602 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OBIO had 4.04% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.37 days to cover at the same settlement.
- Reported short interest (shares) 2,425,602
- Short interest (% of shares outstanding) 4.04%
- Prior settlement (shares) 2,588,912
- Reported change -6.31%
- Days to cover (reported) 13.37
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Boston Scientific (BSX)
- Abbott Laboratories (ABT)
- Edwards Lifesciences (EW)
- Philips (PHG)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OBIO vs…
Frequently asked questions
What does ORCHESTRA BIOMED HOLDINGS INC (OBIO) do?
Orchestra BioMed is a biomedical innovation company developing late-stage clinical medical device candidates through strategic partnerships with market-leading device manufacturers. The company's flagship programs are AVIM Therapy, a bioelectronic treatment for hypertension integrated into cardiac pacemakers (in collaboration with Medtronic), and Virtue Sirolimus AngioInfusion Balloon, a drug-coated balloon for coronary artery disease.
What sector is ORCHESTRA BIOMED HOLDINGS INC (OBIO) in?
ORCHESTRA BIOMED HOLDINGS INC (OBIO) is classified in the Health Care sector. Its industry is Cardiovascular medical devices and bioelectronic therapies. It trades on NASDAQ.
Who are ORCHESTRA BIOMED HOLDINGS INC's (OBIO) competitors?
Notable peers of ORCHESTRA BIOMED HOLDINGS INC (OBIO) include Medtronic, Boston Scientific, Abbott Laboratories, Edwards Lifesciences and Philips. This peer set is informational only — not financial advice.
Is ORCHESTRA BIOMED HOLDINGS INC (OBIO) overbought or oversold right now?
ORCHESTRA BIOMED HOLDINGS INC (OBIO) is currently in overbought territory (its 14-day RSI is 73, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OBIO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.